MedTrace Logo

Treatment of Patients With Anxiety Disorder (0777-022)

NCT00539578 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2015-11-02

No results posted yet for this study

Summary

The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

MK0777

Duration of Treatment: 4 weeks

DRUG

Comparator: placebo (unspecified)

Duration of Treatment: 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2003-02-28
Completion
2003-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00539578 on ClinicalTrials.gov